These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 8867866)

  • 41. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
    Ariga T; Kawamura N; Sakiyama Y
    Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene transfer therapy for heritable disease: cell and expression targeting.
    Mitani K; Clemens PR; Moseley AB; Caskey CT
    Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):217-24. PubMed ID: 8097051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y; Ariga T; Ohtsu M
    Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperbilirubinemia and rapid fatal hepatic failure in severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID).
    Kühl JS; Schwarz K; Münch A; Schmugge M; Pekrun A; Meisel C; Wahn V; Ebell W; von Bernuth H
    Klin Padiatr; 2011 Mar; 223(2):85-9. PubMed ID: 21271505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us.
    Rappeport JM; O'Reilly RJ; Kapoor N; Parkman R
    Immunol Allergy Clin North Am; 2010 Feb; 30(1):17-30. PubMed ID: 20113884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term expression of retroviral-transduced adenosine deaminase in human primitive hematopoietic progenitors.
    Mitani K; Wakamiya M; Caskey CT
    Hum Gene Ther; 1993 Feb; 4(1):9-16. PubMed ID: 8461384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates.
    Schmidt M; Carbonaro DA; Speckmann C; Wissler M; Bohnsack J; Elder M; Aronow BJ; Nolta JA; Kohn DB; von Kalle C
    Nat Med; 2003 Apr; 9(4):463-8. PubMed ID: 12640448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene therapy for adenosine deaminase deficiency.
    Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.
    Carbonaro Sarracino D; Tarantal AF; Lee CC; Martinez M; Jin X; Wang X; Hardee CL; Geiger S; Kahl CA; Kohn DB
    Mol Ther; 2014 Oct; 22(10):1803-16. PubMed ID: 24925206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
    Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
    Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures.
    Stewart AK; Sutherland DR; Nanji S; Zhao Y; Lutzko C; Nayar R; Peck B; Ruedy C; McGarrity G; Tisdale J; Dubé ID
    Hum Gene Ther; 1999 Aug; 10(12):1953-64. PubMed ID: 10466629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells.
    Kaptein LC; Van Beusechem VW; Rivière I; Mulligan RC; Valerio D
    Hum Gene Ther; 1997 Sep; 8(13):1605-10. PubMed ID: 9322093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
    Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
    Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
    Kohn DB; Weinberg KI; Nolta JA; Heiss LN; Lenarsky C; Crooks GM; Hanley ME; Annett G; Brooks JS; el-Khoureiy A
    Nat Med; 1995 Oct; 1(10):1017-23. PubMed ID: 7489356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells.
    Lim B; Apperley JF; Orkin SH; Williams DA
    Proc Natl Acad Sci U S A; 1989 Nov; 86(22):8892-6. PubMed ID: 2573068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
    Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
    J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
    Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
    Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.